Skip to content
Open access

B cell receptor–based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens

Jul 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 65 references
Medicine

TL;DR

A scalable approach for isolating tumor-reactive antibodies is developed and the landscape of potential targets for cancer immunology and immunotherapy expands the landscape of potential targets for cancer immunology and immunotherapy.

Abstract

Tumor-associated B cell responses are frequently observed in tumors and their draining lymph nodes, yet their antigen specificities and functional potential remain incompletely defined. Historically, intracellular antigens have been largely disregarded in tumor antigen mining and discovery efforts. In particular, the extent to which intracellular tumor antigens can be effectively targeted by antibodies and the cellular immune system has remained unclear, poorly characterized, and therapeutically underexploited. We developed a high-throughput platform combining hybridoma generation with unbiased antigen-based flow cytometric enrichment to isolate tumor-reactive monoclonal antibodies. Using a murine 4T1 triple-negative breast cancer model engineered to express the intracellular protein ZsGreen1 (ZsG), we characterized B cell responses and selected antigen-specific hybridomas via fluorescence-activated cell sorting. Antibody specificity was validated using biochemical and cellular assays, and in vivo activity was evaluated following systemic administration. Translational applicability was assessed using hybridomas generated from human tonsillar and peripheral blood B cells. Tumor growth elicited a class-switched, antigen-specific B cell response against the intracellular ZsG antigen. Hybridomas retained a dual phenotype, expressing both surface B cell receptors and secreted immunoglobulins, enabling efficient antigen-driven selection. Isolated monoclonal antibodies recognized native intracellular epitopes that were not detectable using conventional screening approaches. Notably, systemic administration of an anti-ZsG antibody was associated with reduced tumor growth in early established tumors in vivo, supporting functional antibody activity under these conditions. Furthermore, biotinylated tumor lysates enabled unbiased identification of additional tumor-reactive antibodies, and the platform was successfully extended to human B cells. These findings support the accessibility of intracellular tumor antigens to antibody recognition and establish a framework for discovering antibodies targeting this antigen class. The platform described here provides a scalable approach for isolating tumor-reactive antibodies and expands the landscape of potential targets for cancer immunology and immunotherapy.

Read PDF

Similar papers

Open access Nov 2026

T cell-mediated antibody-dependent cellular cytotoxicity provides a therapeutic approach for solid cancers.

The clinical success of chimeric antigen receptor T cells in treating hematological malignancies has highlighted the immense therapeutic potential of engineering T cells with synthetic receptors. However, the limited availability of tumor-specific antigens and the poor ability of T cells to infiltrate solid tumor cores...

Alon Richter, S. Dotan, Petr Shendrik et al. · 0 citations
Open access Oct 2026

Tumor-antigen-specific polyclonal antibodies suppress tumor growth and metastasis in heterogeneous solid tumors

Introduction Tumor heterogeneity and signaling redundancy limit the efficacy of monospecific antibody therapies in solid malignancies. Here we used our platform of glyco-humanized polyclonal antibodies (GH-pAb), to investigate whether targeting multiple tumor-associated antigens provides integrated anti-tumor activity....

C. Ciron, O. Dauphouy, P. Morice et al. · 0 citations
Open access Oct 2026

A dual-function XCL1-CD40L mRNA adjuvant potentiates cancer vaccines by coordinating DC recruitment and maturation

Background Despite the significant promise of mRNA tumor vaccines in treating solid tumors, their clinical response rate is constrained by the low effectiveness of antigen presentation resulting from the immune-suppressive tumor microenvironment (TME). Conventional type 1 dendritic cells (cDC1) are pivotal in antigen c...

Chun-Jie Wu, Wan-Xuan Shao, Ya-Di Liu et al. · 0 citations
Open access Oct 2026

Development and preclinical evaluation of tetraspecific antibodies in combination with ex vivo expanded NK cells infusion for improved control of esophageal cancer

Abstract Background Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous, leading to limited drug effectiveness and resistance. Antibody therapies offer limited benefits due to low response rates. Multispecific antibodies, targeting multiple tumor antigens and natural killer (NK)-cell receptors, may overco...

Ya-Fei Liu, Xue-Yuan Fan, Xue-Yang Zuo et al. · 0 citations
Review Open access Nov 2026

T-cell engagers in solid tumors: challenges and emerging strategies

The structural and mechanistic foundations of TCE activity are examined, including antibody fragment–based constructs, IgG-like bispecific antibodies, T-cell receptor–based engagers, and emerging multispecific platforms, which are positioning TCEs as an increasingly adaptable and durable therapeutic platform for solid...

J. Forero, R. Jani, Xena Zheng et al. · 0 citations
Open access Oct 2026

Screening for Tumor-Specific Antibodies by Yeast Display of Native Repertoires of Tumor-Infiltrating B Cells

Tumors are neoplasms that can be recognized by a patient’s immune system. Recognition of tumor antigens (TAs) triggers the recruitment and proliferation of tumor-infiltrating lymphocytes. Although tumor-infiltrating T cells have long been the primary focus of research, B cells also accumulate in tumors and participate...

Y. R. Vereveyko, D. Malabuiok, E. A. Faizullina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.